| Bioactivity | Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung[1]. |
| Target | KD: 0.113 nM (RSV prefusion F protein) |
| Invitro | Gontivimab (0-100000 nM) 显示出抗病毒活性，对 RSV-A、RSV-B 18537 菌株的 IC50 分别为 0.1、0.4 nM[1]。Gontivimab 与 F 蛋白的抗原位点 II 结合[1]。 |
| In Vivo | Gontivimab (1-68 mg/kg；鼻内给药或雾化) 降低大鼠鼻腔和肺部的 RSV 负荷[1]。 Animal Model: |
| Name | Gontivimab |
| CAS | 1257358-38-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Detalle L, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. |